AFDN and acute myeloid leukemia: The most common KMT2A fusion partners in AML patients include AF9 (MLLT3), AF10 (MLLT10), KMT2A-PTDs, ELL, AF6 (AFDN), ENL (MLLT1), and MLLT11 (Table 1) [12].